- Key note speaker Anthony Geall, Ph.D., Chief Scientific Officer of Precision Nanosystems to discuss current, viable efforts in Moderna’s vaccine clinical trial.
- Foundation celebrates 25th anniversary by highlighting the need for reliable, science based information in the era of COVID.
The Doris A. Howell Foundation will mark its 25th anniversary with the key note presentation “What are RNA Vaccines and Why is the New Vaccine Technology Being Used Against COVID-19?” The virtual presentation, on Friday, Nov. 13 at noon, will feature Precision Nanosystems’ Chief Scientific Officer, Andrew Geall, Ph.D. He is an expert on mRNA vaccine development and is currently working on COVID-19 vaccines to address the current pandemic.
RNA vaccines are a relatively recent innovation but are at the forefront of the many vaccine technologies providing solutions for the COVID-19 pandemic. This talk will describe the different types of vaccines being developed, with a focus on how RNA vaccines are different to conventional vaccine technologies and how they work. It will conclude with a review of the available published clinical data.
“There are multiple sources of information regarding the status of the vaccine development for COVID. The latest polls are showing that, even though the current clinical trials constitute the largest effort in our scientific history, over 40% of Americans are on the fence about getting vaccinated,” comments Marla Black, Executive Director of the Howell Foundation. “Understanding new COVID-19 vaccine development technologies in vaccine development will drive the decisions we make regarding our health, which is critical.”
Dr. Geall will give an overview of the different types of vaccines being developed. The presentation will focus on mRNA vaccines, why they are different from the conventional technologies, and what to expect in the coming years. He will also present the latest published scientific findings regarding the results of his clinical trials.
“While we typically invite experts to present scientific research that directly affects women’s health, in this occasion we determined that having reliable information on such an important public health matter was of the upmost importance,” comments Carol Tuggey, Howell Foundation 2020 Chairperson. “And what a wonderful way to celebrate our 25th anniversary than by providing our audience with the most updated and relevant information on vaccine development technologies!”
To register, please visit www.howellfoundation.org.
About the Howell Foundation:
The Doris A. Howell Foundation for Women’s Health Research exists to advance women’s health and is committed to keeping the women in our community healthy. For 25 years, the Howell Foundation serves to close the gap in medical research and eliminate gender bias in the development of treatments and medications. By supporting the research that will improve the care women receive, and by empowering them with knowledge and resources to advocate for themselves, the Howell Foundation contributes to the long-term health and well-being of women, their families, and the communities in which they serve.
Since its founding in 1995, the organization has awarded more than 250 undergraduate and graduate research scholarships, and has produced over 100 women’s health presentations. In 2013, it expanded its service to include community research grants that bridge the latest findings and women in under-served communities.